利拉鲁肽和阿必鲁泰是治疗2型糖尿病的新靶点药物，较已有的口服降糖药降糖效果好、副作用较小，而且可以减轻体质量，因此有广阔的应用前景。作为新一代降糖新药，利拉鲁肽是一种短效胰高血糖素样肽-1（GLP-1）类似物，阿必鲁泰是一种长效GLP-1类似物，两者既有共同之处，又有区别。总结这二种抗糖尿病新药的临床应用和不良反应研究进展，为临床合理用药以及新药研发提供思路。

Liraglutide and Albiglutide is a new target for the treatment of type 2 diabetes, than the hypoglycemic effect of oral hypoglycemic drugs, less side effects, but also can reduce weight, so it has broad application prospects. As a new generation of drugs, Liraglutide is a short acting glucagon like peptide-1 (GLP-1) analogs, Albiglutide a will is a long-acting GLP-1 analogues, both similarities and differences. The research progress of clinical application and adverse reaction of summarizing these two kinds of anti diabetic drugs, provide ideas for clinical rational use of drugs and drug development.